Prospective study on the effect of prophylactic octreotide administration in preventing pancreatic fistula after pancreatoduodenectomy
徐煜,付学良,刘德军,霍砚淼,刘巍,张军峰,孙勇伟,杨建宇,花荣
DOI: https://doi.org/10.3760/cma.j.cn115667-20211222-00222
2022-01-01
Abstract:Objective:To evaluate the effect of prophylactic octreotide administration on pancreaticoduodenectomy (PD)associated postoperative pancreatic fistula (POPF), total complications, peri-operative death and postoperative in-hospital days.Methods:From January 2020 to August 2021, 148 patients who underwent PD in the Department of Biliary-Pancreatic Surgery in Ren Ji Hospital affiliated with School of Medicine of Shanghai Jiao Tong University were recruited into this single-center randomized control double-blinded clinical trial. Patients were randomly assigned into octreotide group (
n=74) and control group (
n=74). Octreotide group was subcutaneously injected with 0.1 mg (1 ml) octreotide after preoperative anesthesia, and was subcutaneously injected with the same dose every 8 hours for 5 days, with a total of 16 doses. Control group was injected with 1 ml normal saline in the same way, and relevant clinical data and indicators of the two groups were recorded. The primary endpoint was clinically relevant pancreatic fistula, and the secondary endpoints were total complications, perioperative death and postoperative in-hospital days. Univariate and multivariate logistic regression analysis were used to screen the risk factors of clinically related POPF after PD.
Results:120 patients were finally enrolled, including 61 in octreotide group and 59 in control group. There were no significant differences on age, gender ratio, body mass index, preoperative surgery rate of jaundice reduction, preoperative major biochemical indicators, operation time, intraoperative blood loss, pancreatic duct diameter, pancreatic texture and pathological type composition ratio. The total incidence of clinical relevant POPF was 8.3%, and there were no significant differences on biochemical leakage (4.9%
vs 8.5%,
P=0.435), grade B fistula (4.9%
vs 8.5%,
P=0.435) and grade C fistula (1.6%
vs 1.7%,
P=0.981). The total complication incidence (24.5%
vs 28.8%,
P=0.601), perioperative mortality (0
vs 3.3%,
P=0.147) and postoperative in-hospital days (20.6±11.1 d
vs 19.5±12.2 d,
P=0.633) were not significantly different between two groups. Univariate analysis showed that preoperative serum albumin level <30 g/L(
P<0.001) and pathological type of pancreatic ductal adenocarcinoma (
P=0.036) were independent risk factors for POPF after PD, while multivariate analysis found no statistically significant risk factors.
Conclusions:Octreotide can neither reduce the incidences of POPF, total complications and postoperative mortality, nor shorten postoperative in-hospital days. However, for patients with preoperative hypoproteinemia and (or) the pathological type of pancreatic duct adenocarcinoma, the prophylactic use of octreotide during PD and after PD may reduce the occurrence of POPF.